Study of elritercept for anemia in low-risk MDS needing transfusions
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests an investigational drug called elritercept for adults with a specific type of low-risk MDS (myelodysplastic syndromes) who have anemia (low red blood cells) and need regular blood transfusions. The goal is to see if elritercept can reduce or eliminate the need for transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with a low-risk type of MDS (very low, low, or intermediate risk).
- You have needed between 4 and 7 or more red blood cell transfusions in the last 16 weeks, with at least one transfusion in each 8-week period.
- Your body has either stopped responding to or cannot tolerate standard treatments for anemia (like erythropoietin), or your natural erythropoietin level is very high.
- You have not used certain other MDS treatments like lenalidomide, azacitidine, or luspatercept in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests elritercept, a medicine meant to improve anemia (low blood count) in adults with certain lower-risk bone marrow disorders called MDS. If you qualify, the study may help reduce the need for blood transfusions or improve anemia symptoms.
This Phase 1/2 study tests luspatercept combined with another approach in people with low-risk myelodysplastic syndrome (MDS) who are not responding to or cannot use ESA (a common anemia treatment). It may help improve anemia (low hemoglobin), reduce transfusions, and control the disease if you fit the specific criteria.
This trial tests an investigational drug called roxadustat to see if it can help people with a certain type of low-risk MDS who need frequent red blood cell transfusions. It's for patients who haven't responded to other anemia treatments.
This trial tests an investigational drug called TAK-226 for Japanese patients with a type of bone marrow disorder called lower-risk myelodysplastic syndromes (MDS) who have anemia. It aims to see if the drug can help reduce the need for red blood cell transfusions or improve symptoms like fatigue.
This study tests a new drug, momelotinib, for people with a low-risk form of myelodysplastic syndrome (MDS) who need red blood cell transfusions and have already tried one other treatment (like ESAs or luspatercept). The goal is to see if momelotinib can help reduce transfusion needs.
This trial tests an experimental drug, HS-20106, to see if it can improve low red blood cell counts (anemia) for people with a certain type of bone marrow disorder called myelodysplastic syndromes (MDS), which is not high risk. It might be an option if you have not received certain prior treatments.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.